Bioequivalence studies for levothyroxine.

Area of Science:

• Pharmacokinetics and Drug Development
• Regulatory Science
• Pharmaceutical Policy

Background:

• Brand-name manufacturers challenge FDA guidance on levothyroxine bioavailability and bioequivalence studies.
• Concerns raised regarding the handling of endogenous drug levels and PK parameter ratios in equivalence assessments.
• Potential public health risks cited due to the perception of levothyroxine as a narrow therapeutic index drug.

Purpose of the Study:

• To evaluate the adequacy of the current FDA guidance for levothyroxine bioavailability and bioequivalence studies.
• To demonstrate that the recommended methods ensure the acceptance of therapeutically equivalent products.
• To address challenges posed by brand-name manufacturers regarding equivalence criteria.

Main Methods:

• Description of the procedure recommended in the current FDA Guidance for Levothyroxine.
• Analysis of the FDA's criteria for acceptance of bioequivalence.
• Review of safety and efficacy profiles of generic levothyroxine products approved under FDA guidances.

Main Results:

• The current FDA guidance and recommended methods are demonstrated to be adequate for assessing levothyroxine bioequivalence.
• The methods ensure that therapeutically equivalent products are accepted.
• No safety or efficacy differences have been observed for generic levothyroxine products approved via FDA guidances compared to their brand counterparts.

Conclusions:

• The FDA's current guidance for levothyroxine bioavailability and bioequivalence studies is scientifically sound and adequate.
• The established criteria effectively identify therapeutically equivalent generic levothyroxine products.
• Concerns raised by brand-name manufacturers regarding the guidance's ability to differentiate products with minor potency differences are addressed and refuted by evidence of safety and efficacy.